Results 231 to 240 of about 206,755 (278)
Immune Mechanisms of Platelet Refractoriness
The International Journal of Artificial Organs, 1998 Multiple platelet transfusions may prove ineffective in approximately 40% of patients treated for bone marrow aplasia. This condition is known as platelet refractoriness and is diagnosed by evaluating the corrected count increment following platelet transfusion.
F. Fischetti, F. Tedesco
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Platelet refractoriness associated with platelets stored in platelet additive solution
Transfusion, 2022Peer Reviewed ; http://deepblue.lib.umich.edu/bitstream/2027.42/173122/1/trf16941.pdf ; http://deepblue.lib.umich.edu/bitstream/2027.42/173122/2/trf16941_am ...
Laura Cooling +4 more
openaire +3 more sources
Platelet transfusion: Alloimmunization and refractoriness
Seminars in Hematology, 2020The transfusion of platelets for both prophylaxis and treatment of bleeding is relevant to all areas of medicine and surgery. Historically, guidance regarding platelet transfusion has been limited by a lack of good quality clinical trials and so has been based largely on expert opinion. In recent years however there has been renewed interest in methods
Catherine F. Prodger +4 more
openaire +2 more sources
Survey of Current Practice for Monitoring and Management of Platelet Refractoriness in Italy
Transfusion and Apheresis Science, 2012 Platelet transfusion failure is a common phenomenon affecting from 7% to 34% of haematology-oncology patients. Monitoring the efficacy of platelet transfusion through the evaluation of a post-transfusion platelet count and clinical response represent an ...
Alessandra Pompa +2 more
exaly +2 more sources
Causes of refractoriness to platelet transfusion
Current Opinion in Hematology, 1995Platelet refractoriness is a multifactorial problem that often leads to aggressive measures in an attempt to treat a thrombocytopenic patient. Identification of the underlying causes should allow for prevention and management regimens to improve both transfusion practice and patient outcome.
R C, Friedberg, P D, Mintz
openaire +2 more sources
Audit of Practice in Platelet Refractoriness
Vox Sanguinis, 1997Abstract Objectives: A significant number of patients become refractory to platelet transfusion and prompt investigation of the cause will encourage appropriate selection of platelet products. Methods: We surveyed haematologists to assess perceived practice concerning platelet refractoriness because of the high cost and limited availability of HLA ...
K J, Phekoo +5 more
openaire +2 more sources
Platelet transfusions: The problem of refractoriness
Blood Reviews, 1990Refractoriness is a complication of multiple platelet transfusions in 30-70% of patients with bone marrow failure. The major causes are HLA alloimmunisation and non-immune platelet consumption; the latter is usually found in patients with DIC, septicaemia or splenomegaly.
M F, Murphy, A H, Waters
openaire +2 more sources
Management of the Platelet Refractory Patient
Hematology/Oncology Clinics of North America, 2016Platelet refractoriness occurs when there is an inadequate response to platelet transfusions, which typically has nonimmune causes, but is also associated with alloantibodies to human leukocyte antigens (HLAs) and/or human platelet antigens. Immune-mediated platelet refractoriness is suggested when a 10-minute to 1-hour corrected count increment of ...
Stefanie K, Forest, Eldad A, Hod
openaire +2 more sources
Refractoriness to platelet transfusion
Current Opinion in Hematology, 2002This review discusses the causes of refractoriness to platelet transfusions and presents three options for its management. Platelet refractoriness is a complication of platelet transfusion that affects variable proportions of patients, mostly depending on their diagnosis, previous immunologic stimuli, and type of blood products used for transfusion.
openaire +2 more sources
Vox Sanguinis, 2016 Transfusion support for immune-mediated platelet refractoriness (PR) is clinically challenging, technically laborious and costly. The development of 'EpHLA/EpVix software' has been used successfully to select kidney donors.
Carolina Bonet Bub +2 more
exaly +2 more sources